Inhaled Semaglutide

About Iconovo

Iconovo is a specialized inhalation drug delivery company offering end-to-end development of inhaled therapies. Its core business model combines a portfolio of patented dry powder inhaler platforms with integrated formulation expertise to partner with pharma companies. A key strategic aim is to leverage the patent cliff for biologics by developing inhaled alternatives to injections, exemplified by its pipeline project for inhaled semaglutide. The company is publicly traded and recently secured capital through directed and rights issues to fund its development programs.

Therapeutic Areas